{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:34:01Z","timestamp":1791182041295,"version":"4.1.0"},"reference-count":22,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2012,8,29]],"date-time":"2012-08-29T00:00:00Z","timestamp":1346198400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2013,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Background\u2002<\/jats:bold>\n                    Chronic spontaneous urticaria (CSU), a mast cell\u2010driven condition, is debilitating, common, and hard to treat. Miltefosine, a lipid raft modulator, can inhibit mast cell responses\n                    <jats:italic>in vivo<\/jats:italic>\n                    .\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Objective\u2002<\/jats:bold>\n                    To study the safety and efficacy of systemic miltefosine treatment in CSU patients resistant to standard\u2010dosed antihistamines.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods\u2002<\/jats:bold>\n                    In this investigator\u2010initiated multicentre, randomized, double\u2010blind, placebo\u2010controlled study, CSU patients were treated for 4\u2003weeks with daily doses of up to 150\u2010mg miltefosine (\n                    <jats:italic>n\u2003<\/jats:italic>\n                    =\u200347) or placebo (\n                    <jats:italic>n\u2003<\/jats:italic>\n                    =\u200326). Disease activity was assessed using the urticaria activity score. Safety and tolerability of miltefosine were also assessed.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results\u2002<\/jats:bold>\n                    After 4\u2003weeks of treatment, Urticaria Activity Score (UAS7) levels were substantially more reduced in miltefosine\u2010treated patients (\u22126.3 vs. \u22123.5 in placebo\u2010treated patients;\n                    <jats:italic>P<\/jats:italic>\n                    \u2003=\u20030.05). Also, the number of weals, but not the intensity of pruritus, was significantly reduced in miltefosine\u2010treated patients vs. placebo\u2010treated patients (\n                    <jats:italic>P\u2003<\/jats:italic>\n                    =\u20030.02). In general, adverse events were frequent in both groups (miltefosine: 88%, placebo: 65% of patients) but mostly mild to moderate in severity. We did not observe any serious adverse events.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions\u2002<\/jats:bold>\n                    The results of this study indicate that miltefosine is an effective and safe treatment option for CSU patients who do not respond to standard\u2010dosed antihistamines.\n                  <\/jats:p>","DOI":"10.1111\/j.1468-3083.2012.04689.x","type":"journal-article","created":{"date-parts":[[2012,8,29]],"date-time":"2012-08-29T04:43:08Z","timestamp":1346215388000},"source":"Crossref","is-referenced-by-count":24,"title":["Randomized, double\u2010blind, placebo\u2010controlled study of safety and efficacy of miltefosine in antihistamine\u2010resistant chronic spontaneous urticaria"],"prefix":"10.1111","volume":"27","author":[{"given":"M.","family":"Magerl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Rother","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Bieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Biedermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Brasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Dominicus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Hunzelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Jakob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Mahler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Popp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Sch\u00e4kel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Schlingensiepen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Siebenhaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.C.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Staubach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Wedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Weidner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,8,29]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.04185.x"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2004.08.043"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00105-004-0692-9"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0b013e32832e9af1"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4419-8056-4_7"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4419-8056-4_7"},{"key":"e_1_2_6_8_2","first-page":"118","article-title":"Review of H1 antihistamines in the treatment of chronic idiopathic urticaria","volume":"76","author":"Monroe E","year":"2005","journal-title":"Cutis"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2005.02159.x"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.2174\/138920009787846332"},{"key":"e_1_2_6_11_2","first-page":"752906","article-title":"Lipid rafts in mast cell biology","volume":"2011","author":"Silveira ESAM","year":"2011","journal-title":"J Lipids"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.21.4150"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2011.10-0661"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09434.x"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2008.248"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11745-007-3026-8"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2009.02217.x"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.11.047"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2008.01726.x"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2008.01920.x"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2005.00833.x"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462300007728"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-3083.2012.04689.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-3083.2012.04689.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T00:16:06Z","timestamp":1697328966000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-3083.2012.04689.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,29]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["10.1111\/j.1468-3083.2012.04689.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-3083.2012.04689.x","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717953966.793459490","asserted-by":"object"}]},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,29]]}}}